The changes in total cholesterol, HDL-C, TG and non-HDL-C from baseline at 6 and 12 weeks with rosuvastatin and atorvastatin treatment are displayed in the current slide.

Changes in total cholesterol, LDL-C, HDL-C, and non-HDL-C from baseline were significantly greater in the rosuvastatin group when compared with the atorvastatin group at 6 and 12 weeks (P< 0.01). Reductions in TG were similar in the rosuvastatin and atorvastatin groups.1.

By 12 weeks, HDL-C increased by 10.4% with rosuvastatin when compared with 5.8% with atorvastatin (P<0.01).1 

Reference:

1. Stalenhoef AFH, et al. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. Eur Heart J. 2005;26: 2664–2672.